Abbott Laboratories, Medtronic, Inc. Fortunes to Rise on Heart Stents

Sept. 6 (Bloomberg) -- Abbott Laboratories and Medtronic Inc. are poised to seize a third of the $5 billion in annual heart-stent sales with new versions of the drug-coated devices. Studies suggest the Abbott and Medtronic stents are more effective than artery-opening products sold by market leaders Johnson & Johnson and Boston Scientific Corp. Abbott's new Xience stent may become the top seller because of superior technology, according to Samin Sharma, director of interventional cardiology at Mount Sinai Medical Center, who implants more stents than any other New York doctor.

Back to news